Masayuki Senda

Publication Activity (10 Years)

Years Active: 2019-2020
Publications (10 Years): 8

Top Topics

Glycemic Control

Clinical Practice

Top Venues

Journal of diabetes investigation

Expert opinion on pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Kazunori Utsunomiya, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Ryusuke Koshida, Hiroyuki Kameda, Masahiro Tamura, Kohei Kaku
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT). Journal of diabetes investigation 11 (4) (2020)
Munehide Matsuhisa, Masato Odawara, Takahisa Hirose, Ryusuke Koshida, Masayuki Senda, Yasushi Tanaka, Yasuo Terauchi
Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study). Expert opinion on pharmacotherapy 22 (2) (2020)
Masato Odawara, Munehide Matsuhisa, Takahisa Hirose, Ryusuke Koshida, Masayuki Senda, Yasushi Tanaka, Yasuo Terauchi
Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study). Expert opinion on pharmacotherapy 21 (14) (2020)
Kazunori Utsunomiya, Ryusuke Koshida, Seigo Kakiuchi, Masayuki Senda, Shoko Fujii, Yuji Kurihara, Ryoji Gunji, Kohei Kaku
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT). Journal of diabetes investigation 12 (2) (2020)
Kohei Kaku, Yusuke Naito, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Seigo Kakiuchi, Kazunori Utsunomiya
Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post-marketing study (J-STEP/EL Study). Journal of diabetes investigation 11 (2) (2019)
Yasuo Terauchi, Hisataka Fujiwara, Yuji Kurihara, Hideki Suganami, Masahiro Tamura, Masayuki Senda, Ryoji Gunji, Kohei Kaku
Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study. Journal of diabetes investigation 10 (6) (2019)
Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Hisataka Fujiwara, Kohei Kaku
Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT). Journal of diabetes investigation 10 (5) (2019)
Kazunori Utsunomiya, Masayuki Senda, Seigo Kakiuchi, Hiroyuki Kameda, Masahiro Tamura, Yuji Kurihara, Ryoji Gunji, Shoko Fujii, Kohei Kaku
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world practice: Results of 12-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT). Journal of diabetes investigation 11 (1) (2019)